Study: Use of PET and PET/CT is cost-effective for some cancers

03/31/2010 | HealthImaging.com

German researchers who examined data from Germany, Britain, other European countries and the U.S. found that on a patient basis, the costs for PET and PET/CT procedures are decreasing with the increase in use of the procedures for certain cancers, including nonsmall-cell lung cancer, Hodgkin's disease, non-Hodgkin's lymphoma and colorectal carcinoma. There still is a need for larger trials to determine the cost-effectiveness of the tests for other cancers, the researchers said.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI